medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2005, Number 2

<< Back Next >>

Rev Invest Clin 2005; 57 (2)

Malignant neoplasias in renal transplantation recipients

Gómez-Roel X, León-Rodríguez E

Language: Spanish
References: 13
Page: 225-229
PDF size: 50.57 Kb.


ABSTRACT

Malignancy following renal transplantation is an important medical problem during the long-term follow-up. The overall incidence of cancer at this group of patients is 3 to 5 times higher than the expected incidence in general population by age. The most common malignancies are skin carcinomas and lymphomas. There is retrospective experience in many reports about the association between the intensity of immunosuppression and the higher frequency of malignancy, besides other factors. In our Institution we found similar experience than other series, with 8.28%, of development of malignancies in a follow-up of 7.28 years. We found lower latency with three-drug immunosuppression than with two. To reduce the development of malignancies after renal transplantation must be one of the objectives in future immunossupressive therapy, mainly in the setting of new immunosuppressive drugs like rapamycin.


REFERENCES

  1. Birkeland SA, Lokkegaard H, Store HH. Cancer risk in patients on dialysis and after renal transplantation. Lancet 2000; 355:1886-7.

  2. Peto J. Cancer epidemiology in the last century and the next decade. Nature 2001; 411: 390-5.

  3. Zeier M, Hartschuh W, Wiesel M et al. Malignancy after renal transplantation. Am J Kidney Dis 2002; 39: E5.

  4. Penn I. Tumors after renal and cardiac transplantation. Hematol Oncol Clin NA 1993; 7(2): 431-45.

  5. Morath C, Mueller M, Goldschmidt, et al. Malignancy in renal transplantation. J Am Soc Nephrol 2004; 15(6): 1582-8.

  6. Bouwes Bavinck JN, Hardie DR, Green A, et al. The risk of skin cancer in renal transplant recipients in Queensland, Australia. A follow-up study. Transpl 1996; 61: 715-21.

  7. Birkeland SA, Storm HH, Lamm LU, et al. Cancer risk after transplantation in the Nordic countries, 1964-1986. Int J Cancer 1995; 60: 183-9.

  8. Hoshida Y, Tsukuma H, Yasunaga Y, et al. Cancer risk after renal transplantation in Japan. Int J Cancer 1997; 71: 517-20.

  9. Penn I. Cancers in renal transplant recipients. Adv Ren Replace Ther 2000; 7: 147-56.

  10. Cherikh WS, Kauffman HM, Delmonico FL. A multivariate analysis of discharge immunosuppresion and post-transplant malignancy. Am J Transplant 2001; 1(Suppl. 1): 353-9.

  11. Guba M. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002; 8(2): 128-35.

  12. Penn I. The effect of immunosuppresion on pre-existing malignancies. Ann Transplant 1997; 2: 14-17.

  13. Weiss NS. Risk of breast cancer after renal or cardiac transplantation. Lancet 1995; 346: 1422-3.




2020     |     www.medigraphic.com